Industrials - Germany



Buy (old: Buy) 13.03.2024

EUR 8.20 (old: EUR 8.20)

Excellent growth and profitability, soft order intake; chg.

Topic: MAX released strong FY23 results, with sales and EBITDA in line with expectations and the company's guidance. The sales process of the subsidiary MA micro, which is now recognized as discontinued operations, is still ongoing.

FY23 sales (incl. MA micro) rose by 8.3% to € 443m (eNuW: € 444m), in line with the guidance range of € 410-470m due to a strong contribution from bdtronic (+59% yoy), offsetting the weaker Vecoplan, NSM + Jücker and MA micro. Q4 sales grew slightly by 3.2% yoy to € 117m (eNuW: € 117m). FY23 EBITDA (incl. MA micro) came in at € 43.2m (eNuW: € 43.9m) a 28% increase yoy, hitting the upper end of the guidance range of € 38-44m. This implies a 9.8% margin, up 1.5pp yoy due to normalized material prices and strong performance of bdtronic. Q4 EBITDA increased 155% yoy to € 6.2m (eNuW: € 6.9m) with a margin of 5.3% (+ 3.2pp yoy) due to a weak Q4 in FY22.

Group order intake from continued operations decreased by 16% to € 341m, leading to an order backlog of € 206m (-21% yoy), impacted from investment reluctance due to the ongoing economic uncertainty and higher interest costs. Mind you, FY22 benefited from COVID-19 catch-up effects and FY23 order intake and backlog are still on a historical high level.

Outlook for FY24e for continuing operations: MAX guides for sales of € 390-450m, in line with eNuW (€ 425m), carried by a € 206m group backlog and a healthy order pipeline. FY24e EBITDA should come in between € 31-38m (eNuW: € 32.7m). Despite the lower order backlog, the guidance seems to be in reach due to the postponement of some larger orders from Q4 FY23 into FY24e as well as improving supply chains and material prices.

bdtronic showed a dynamic top- and bottom-line development (see page two), as a result of the fulfillment of the high order backlog and continued strong demand for dispensing and impregnation. Sales increased 59% yoy to € 104m (eNuW: € 94.7m) and EBITDA rose by 58% with a flat development in margins at 14%, due to large investments into growth (e.g. personell, PPE). Order intake rose by 11% yoy to a new record high of € 104m, flagging the technological leadership and ongoing structural trends such as electrification of the automotive industry. Order intake in Q4 came in rather weak at € 11m compared to € 29m in Q4 FY22, due to the postponement of a major order to FY24e. -continued-

Y/E 31.12 (EUR m)	2021	2022	2023	2024e	2025e	2026e
Sales	349.1	342.7	397.4	425.0	459.0	496.1
Sales growth	13.7%	-1.8%	16.0%	7.0%	8.0%	8.1%
EBITDA	25.7	29.4	34.6	32.7	37.9	39.6
Net debt (if net cash=0)	81.5	53.1	77.1	45.0	19.4	41.0
FCF	20.9	-12.1	6.4	31.8	25.6	25.8
Net Debt/EBITDA	3.2	1.8	2.2	1.4	0.5	1.0
EPS pro forma	-0.05	0.43	0.14	0.20	0.29	0.32
EBITDA margin	7.4%	8.6%	8.7%	7.7%	8.2%	8.0%
ROCE	5.5%	9.6%	8.3%	8.3%	9.1%	9.2%
EV/sales	0.7	0.8	0.8	0.6	0.5	0.5
EV/EBITDA	9.6	9.1	8.9	8.4	6.6	5.7
PER	-117.8	13.0	15.2	27.5	19.0	17.5
Adjusted FCF vield	4.7%	8.6%	7.2%	7.9%	9.3%	8.5%

Source: Company data, NuWays, Close price as of 12.03.2024



Market data	
Share price (in €)	5.88
Market cap (in € m)	230.3
Number of shares (in m pcs)	41.1
Enterprise value (in € m)	275.9
Ø trading volume (6 months)	5,854

Identifier							
Bloomberg	MXHN GR						
Reuters	MAXG						
WKN	A2DA58						
ISIN	DE000A2DA588						


Key shareholders						
Günther Group	59.0%					
Free Float	13.3%					
Loys	10.5%					
H&A Fund Services	8.0%					
BWVA	5.0%					
Werner Weber	4.2%					


Estimates changes							
	<u>2024e</u>	<u>2025e</u>	<u>2026e</u>				
Sales	-11%	-10%	-9%				
EBIT	-37%	-32%	-36%				
EPS	-43%	-31%	-35%				

Comment on changes

- Deconsolidation of MA micro
- We adjusted our model for the lower than expected order intake

Sales (2021-26e) 600.0m 450.0m 300.0m 150.0m 0.0m 2021 2022 2023 2024e 2025e 2026e Source: NuWays Research





Company description

MAX Automation is an expert for automation, production and assembly solutions, mostly serving niche applications across various end-markets. The subsidiaries operate in technology and innovative fields including e-mobility, medical, electronics and environmental.

Guidance

- Sales: € 390-450m
- EBITDA: € 31-38m

Update - 13.03.2024



We expect bdtronic to deliver another year of double-digit growth in FY24e (eNuW: 12%).

Vecoplan delivered low-single-digit growth in sales and EBITDA, while margins remained roughly unchanged at 11.5% (FY22: 11.3%). Order intake fell by 15.6% yoy to € 145m, due to investment reluctance in Europe and US and the postponement of orders. However, the highly profitable service business, which accounts for c. 1/3 of sales, recorded significant growth during FY23.

In addition to the improving operating performance, a successful **divestment of the subsidiary MA micro** (company news 08.09.2023) should be a **notable share price catalyst**. This would reveal, that the value of the "parts" clearly exceeds the current Enterprise Value of the MAX Automation group, in our view.

We reiterate our BUY rating with an unchanged € 8.20 PT based on DCF.

	FY 2023	FY 2023	FY 2022	yoy
	reported	eNuW	reported	%
Orders group	341	na	405	-15.7%
Revenue group	397	444	343	16.0%
EBITDA group	34.6	43.9	30.3	14.1%
EBITDA margin	8.7%	9.9%	8.8%	- 0.1 pp
bdtronic				
Orders	103.8	na	93.4	11.2%
Sales	103.80	94.74	65.17	59.3%
EBITDA	14.8	16.2	9.4	57.6%
Margin	14.3%	17.1%	14.4%	- 0.1 pp
Vecoplan				
Orders	145	na	171	-15.7%
Sales	178	185	174	2.2%
EBITDA	20.4	21.3	19.7	3.7%
Margin	11.5%	11.5%	11.3%	+ 0.2 pp
AIM Micro				
Orders	6.0	na	5.1	17.4%
Sales	6.8	7.1	6.0	12.6%
EBITDA	2.1	2.4	1.8	18.6%
Margin	30.9%	33.1%	29.3%	+ 1.6 pp
NSM + Jücker				
Orders	40.2	na	74.7	-46.2%
Sales	55.6	54.9	57.1	-2.5%
EBITDA	5.2	5.1	5.6	-7.1%
Maegin	9.4%	9.3%	9.8%	- 0.5 pp
ELWEMA				
Orders	46.8	na	60.3	-22.3%
Sales	53.2	54.9	40.5	31.4%
EBITDA	4.0	2.8	2.9	38.6%
Margin	7.5%	5.1%	7.1%	+ 0.4 pp
	Discontinu	ued operati	ons	
MA micro group				
Orders	26.2	na	21.0	24.9%
Sales	46.5	47.5	64.3	-27.7%
EBITDA	9.3	10.2	11.2	-17.1%
Margin	20.0%	21.5%	17.4%	+ 2.6 pp

Source: Company data; NuWays

Update - 13.03.2024



3.8%

0.0%

3.8%

30.0%

2.7%

0.0%

2.7%

0.0%

2.7%

3.8%

0.0%

3.8%

30.0%

2.6%

0.0%

2.6%

0.0%

2.6%

Financials

Profit and loss (EUR m)	2021	2022	2023	2024e	2025e	202
Net sales	349.1	342.7	397.4	425.0	459.0	496
Cales growth	13.7%	-1.8%	16.0%	7.0%	8.0%	8.1
crease/decrease in finished goods and work-in-process	4.8	21.3	9.2	7.2	7.7	(
otal sales	353.8	364.0	406.6	432.3	466.7	49
other operating income	19.8	9.3	6.7	11.0	13.8	14
Naterial expenses	174.7	186.1	199.5	212.5	227.2	24
Personnel expenses	122.5	107.0	122.4	141.5	154.2	16
Other operating expenses	50.7	50.9	56.9	56.6	61.2	6
otal operating expenses	328.1	334.6	372.0	399.6	428.8	45
BITDA	25.7	29.4	34.6	32.7	37.9	3
Depreciation	5.0	4.8	5.8	5.1	5.5	
BITA	20.7	24.5	28.8	27.6	32.4	3
mortisation of goodwill	0.0	0.0	5.2	0.0	0.0	
mortisation of intangible assets	9.2	3.1	4.4	6.0	6.0	
mpairment charges	0.0	0.0	0.0	0.0	0.0	
BIT (inc revaluation net)	11.6	21.5	19.2	21.6	26.4	2
nterest income	0.0	0.4	0.1	0.4	0.4	
nterest expenses	8.3	8.8	12.8	11.5	11.0	1
nvestment income	0.0	2.7	4.6	1.4	1.5	
inancial result	-8.3	-5.7	-8.1	-9.7	-9.1	-
Recurring pretax income from continuing operations	3.2	15.8	11.1	11.9	17.2	1
xtraordinary income/loss	0.0	0.0	0.0	0.0	0.0	
arnings before taxes	3.2	15.8	11.1	11.9	17.2	1
ncome tax expense	4.1	-0.8	5.5	3.5	5.1	
let income from continuing operations	-0.9	16.6	5.6	8.4	12.1	1
ncome from discontinued operations (net of tax)	0.0	1.6	-9.6	0.0	0.0	
let income	-0.9	15.0	15.2	8.4	12.1	1
Ainority interest	0.5	0.3	0.0	0.0	0.0	
let profit (reported)	-1.4	14.7	15.2	8.4	12.1	1
Average number of shares	29.5	38.0	41.1	41.1	41.1	4
PS reported	-0.05	0.39	0.37	0.20	0.29	0
rofit and loss (common size)	2021	2022	2023	2024e	2025e	202
let sales	100.0%	100.0%	100.0%	100.0%	100.0%	100.
ales growth	13.7%	-1.8%	16.0%	7.0%	8.0%	8.
ncrease/decrease in finished goods and work-in-process	1.4%	6.2%	2.3%	1.7%	1.7%	0.
otal sales	101.4%	106.2%	102.3%	101.7%	101.7%	100.
Other operating income	5.7%	2.7%	1.7%	2.6%	3.0%	3.
laterial expenses	50.0%	54.3%	50.2%	50.0%	49.5%	49.
ersonnel expenses	35.1%	31.2%	30.8%	33.3%	33.6%	33.
Other operating expenses	14.5%	14.9%	14.3%	13.3%	13.3%	12.
otal operating expenses	94.0%	97.7%	93.6%	94.0%	93.4%	92.
BITDA	7.4%	8.6%	8.7%	7.7%	8.2%	8.
Depreciation	1.4%	1.4%	1.5%	1.2%	1.2%	1.
BITA	5.9%	7.2%	7.2%	6.5%	7.1%	6.
mortisation of goodwill	0.0%	0.0%	1.3%	0.0%	0.0%	0.
mortisation of intangible assets	2.6%	0.9%	1.1%	1.4%	1.3%	1.
mpairment charges	0.0%	0.0%	0.0%	0.0%	0.0%	0.
BIT (inc revaluation net)	3.3%	6.3%	4.8%	5.1%	5.7%	5.
nterest income	0.0%	0.1%	0.0%	0.1%	0.1%	0.
nterest expenses	2.4%	2.6%	3.2%	2.7%	2.4%	2.
nvestment income	0.0%	0.8%	1.2%	0.3%	0.3%	0.
Financial result	neg.	neg.	neg.	neg.	neg.	n
Pocurring protay income from continuing enerations	Λ 00/.	4 60/	2 00/	2 90/	2 00/	2

0.9%

0.0%

0.9%

-0.3%

0.0%

-0.3%

0.1%

-0.4%

127.6%

4.6%

0.0%

4.6%

-5.1%

4.8%

0.5%

4.4%

0.1%

4.3%

Net profit (reported)
Source: Company data, NuWays

Extraordinary income/loss

Earnings before taxes

Tax rate

Net income

Minority interest

Recurring pretax income from continuing operations

Net income from continuing operations

Income from discontinued operations (net of tax)

NuWays AG 3

2.8%

0.0%

2.8%

1.4%

-2.4%

3.8%

0.0%

3.8%

25.0%

2.8%

0.0%

2.8%

30.0%

2.0%

0.0%

2.0%

0.0%

2.0%

Update - 13.03.2024



Balance sheet (EUR m)	2021	2022	2023	2024e	2025e	2026e
Intangible assets	54.4	54.5	37.8	33.0	27.1	20.9
Property, plant and equipment	43.2	46.1	50.7	53.3	56.1	58.1
Financial assets	7.1	42.6	47.4	47.4	47.4	47.4
FIXED ASSETS	104.8	143.2	135.9	133.7	130.6	126.4
Inventories	53.5	89.6	92.5	88.5	94.7	101.9
Accounts receivable	31.9	40.1	49.8	46.7	50.4	54.5
Other assets and short-term financial assets	37.2	52.1	41.6	44.6	43.0	43.0
Liquid assets	30.2	35.7	26.6	43.2	58.8	84.6
Deferred taxes	10.6	15.6	16.0	16.5	16.9	17.1
Deferred charges and prepaid expenses	9.6	0.0	0.0	0.0	0.0	0.0
CURRENT ASSETS	173.0	233.1	249.1	239.5	264.2	301.2
TOTAL ASSETS	277.8	376.3	385.0	373.3	394.8	427.5
SHAREHOLDERS EQUITY	39.8	93.1	114.9	123.3	151.3	178.7
MINORITY INTEREST	0.8	0.8	0.0	0.0	0.0	0.0
Provisions for pensions and similar obligations	0.0	0.6	0.5	0.5	0.5	0.5
Other provisions and accrued liabilities	14.7	14.4	15.2	15.2	15.6	16.5
Short-term liabilities to banks	86.3	0.5	0.6	0.6	0.6	0.6
Accounts payable	32.2	62.9	52.2	47.9	51.0	55.1
Advance payments received on orders	0.0	0.0	0.0	0.0	0.0	0.0
Other liabilities (incl. from lease and rental contracts)	62.1	61.4	38.3	38.6	38.6	38.6
Deferred taxes	7.9	10.3	9.7	10.1	10.1	10.4
Deferred income	0.0	0.0	0.0	0.0	0.0	0.0
CURRENT LIABILITIES	94.2	124.3	90.6	86.5	89.6	93.7
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	277.8	376.3	385.0	373.3	394.8	427.5
	0004	0000	0000	2004	0005	0000
Balance sheet (common size)	2021	2022 14.5%	2023 9.8%	2024e 8.9%	2025e 6.9%	2026e
Intangible assets	19.6%		13.2%	14.3%	14.2%	4.9%
Property, plant and equipment Financial assets	15.6% 2.6%	12.2% 11.3%	12.3%	14.3%	12.0%	13.6% 11.1%
FIXED ASSETS	37.7%	38.1%	35.3%	35.8%	33.1%	29.6%
Inventories	19.3%	23.8%	24.0%	23.7%	24.0%	23.8%
	11.5%	10.6%	12.9%	12.5%	12.8%	12.8%
Accounts receivable Other assets and short-term financial assets	13.4%	13.8%	10.8%	11.9%	10.9%	10.1%
	10.9%	9.5%	6.9%	11.6%	14.9%	19.8%
Liquid assets Deferred taxes	3.8%	9.5% 4.2%	4.2%	4.4%	4.3%	4.0%
	3.5%	0.0%	0.0%	0.0%	0.0%	0.0%
Deferred charges and prepaid expenses CURRENT ASSETS	62.3%	61.9%	64.7%	64.2%	66.9%	70.4%
TOTAL ASSETS	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
101/12/100210	1001070	1001070	1001070	1001070	1001070	1001070
SHAREHOLDERS EQUITY	14.3%	24.7%	29.8%	33.0%	38.3%	41.8%
MINORITY INTEREST	0.3%	0.2%	0.0%	0.0%	0.0%	0.0%
Provisions for pensions and similar obligations	0.3%	0.1%	0.1%	0.1%	0.1%	0.1%
Other provisions and accrued liabilities	5.3%	3.8%	3.9%	4.1%	4.0%	3.9%
Short-term liabilities to banks	31.1%	0.1%	0.2%	0.2%	0.2%	0.1%
Accounts payable	11.6%	16.7%	13.6%	12.8%	12.9%	12.9%
Advance payments received on orders	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Other liabilities (incl. from lease and rental contracts)	22.3%	16.3%	10.0%	10.3%	9.8%	9.0%
Deferred taxes	2.8%	2.7%	2.5%	2.7%	2.6%	2.4%
Deferred income	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CURRENT LIABILITIES	33.9%	33.0%	23.5%	23.2%	22.7%	21.9%
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Source: Company data, NuWays

Update - 13.03.2024



Cash flow statement (EUR m)	2021	2022	2023	2024e	2025e	2026e
Net profit/loss	-0.9	15.0	15.2	8.4	12.1	13.2
Depreciation of fixed assets (incl. leases)	5.0	4.9	5.8	5.1	5.5	6.9
Amortisation of goodwill & intangible assets	9.2	6.5	10.2	6.0	6.0	5.0
Others	-5.0	-8.5	-11.4	0.3	0.0	0.0
Cash flow from operating activities	18.0	-13.5	7.1	30.9	22.9	22.8
Increase/decrease in inventory	-10.2	-29.7	-7.3	4.0	-6.1	-7.3
Increase/decrease in accounts receivable	-4.8	-8.3	-12.8	3.1	-3.7	-4.1
Increase/decrease in accounts payable	8.5	8.4	-22.1	-4.3	3.1	4.1
Increase/decrease in other working capital positions	0.0	0.0	8.5	0.0	0.0	0.0
Increase/decrease in working capital	-6.6	-29.6	-33.7	2.7	-6.8	-7.2
Cash flow from operating activities	27.7	-2.8	17.2	42.0	36.7	37.7
CAPEX	6.8	9.3	10.8	10.2	11.0	11.9
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	0.1	0.1	0.0	0.0	0.0	0.0
Income from asset disposals	3.6	1.0	1.7	0.0	0.0	0.0
Cash flow from investing activities	-3.3	-8.4	-9.1	-10.2	-11.0	-11.9
Cash flow before financing	24.4	-11.2	8.2	31.8	25.6	25.8
Increase/decrease in debt position	-37.0	23.8	-5.9	-15.5	-10.0	0.0
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.9	0.0	0.0	0.0	0.0
•						
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0
Others	-5.0	-8.5	-11.4	0.3	0.0	0.0
Effects of exchange rate changes on cash	0.1	0.5	0.0	0.0	0.0	0.0
Cash flow from financing activities	-42.0	16.3	-17.3	-15.2	-10.0	0.0
Increase/decrease in liquid assets	-17.5	5.6	-9.1	16.6	15.6	25.8
Liquid assets at end of period	30.2	35.7	26.6	43.2	58.8	84.6
Elquia accete at ona or perioa	00.2	CO	20.0		00.0	00
Key ratios (EUR m)	2021	2022	2023	2024e	2025e	2026e
	2021	2022	2023	20246	20256	20206
P&L growth analysis	10 =0/	4.00/	10.00/		2.22/	0.40/
Sales growth	13.7%	-1.8%	16.0%	7.0%	8.0%	8.1%
EBITDA growth	354.7%	14.1%	17.7%	-5.5%	15.9%	4.6%
EBIT growth	-159.3%	85.7%	-10.7%	12.8%	22.1%	4.9%
EPS growth	-94.7%	-914.0%	-4.7%	-44.8%	44.9%	8.7%
Efficiency						
Sales per employee	218.9	215.1	245.4	250.0	257.1	267.3
	16.1	18.4	21.3	19.2	21.2	21.3
EBITDA per employee						
No. employees (average)	1,595	1,593	1,619	1,700	1,785	1,856
Balance sheet analysis						
Avg. working capital / sales	14.7%	16.6%	18.0%	18.1%	20.1%	19.0%
Inventory turnover (sales/inventory)	3.6	2.6	2.2	2.4	2.4	2.4
Accounts receivable turnover	11.8	9.5	8.8	9.1	9.1	9.1
Accounts payable turnover	12.5	7.2	6.9	8.9	9.0	9.0
Cash flow analysis			0.0	0.0	0.0	0.0
Free cash flow	20.9	-12.1	6.4	21.0	25.6	25.8
			6.4	31.8		
Free cash flow/sales	6.0%	-3.5%	1.6%	7.5%	5.6%	5.2%
FCF / net profit	neg.	neg.	42.5%	379.7%	211.5%	195.7%
Capex / sales	2.0%	2.7%	2.7%	2.4%	2.4%	2.4%
Solvency						
Net debt	81.5	53.1	77.1	45.0	19.4	41.0
Net Debt/EBITDA	3.2	1.8	2.2	1.4	0.5	1.0
Dividend payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest paid / avg. debt	6.0%	6.3%	9.4%	8.6%	8.0%	8.4%
	0.076	0.5 /6	9.4 /0	0.076	0.070	0.4 /0
Returns	= =^/	0.001	0.001	0.007	0.407	0.007
ROCE	5.5%	9.6%	8.3%	8.3%	9.1%	9.2%
ROE	-3.5%	15.8%	13.2%	6.8%	8.0%	7.4%
Adjusted FCF yield	4.7%	8.6%	7.2%	7.9%	9.3%	8.5%
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
DPS	0.0	0.0	0.0	0.0	0.0	0.0
EPS reported	-0.05	0.39	0.37	0.20	0.29	0.32
·	-0.03		41.1	41.1		
	20 E		411	411	41.1	41.1
Average number of shares	29.5	38.0	71.1			
Valuation ratios						
Valuation ratios P/BV	4.1	2.3	2.0	1.9	1.5	1.3
Valuation ratios						1.3 0.5
Valuation ratios P/BV	4.1	2.3	2.0	1.9	1.5	
Valuation ratios P/BV EV/sales EV/EBITDA	4.1 0.7 9.6	2.3 0.8 9.1	2.0 0.8 8.9	1.9 0.6 8.4	1.5 0.5 6.6	0.5 5.7
Valuation ratios P/BV EV/sales	4.1 0.7	2.3 0.8	2.0 0.8	1.9 0.6	1.5 0.5	0.5

Update - 13.03.2024



Disclosures

Disclosures regarding research publications of NuWays AG pursuant to section 85 of the German Securities Trading Act (WpHG)

Indication of conflict of interest

It is essential that any research recommendation is fairly presented and discloses interests of indicates relevant conflicts of interest. Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analysed company. A conflict of interest is presumed to exist in particular if NuWays AG

- (1) or any other person belonging to the same group with it was part of a consortium within the past twelve months that issued the financial instruments of the analysed company by way of a public offer.
- (2) or any other person belonging to the same group with it has entered into an agreement on the production of the research report with the analysed company.
- (3) or any other person belonging to the same group with it has been party to an agreement on the provision of investment banking services with the analysed company or have received services or a promise of services under the term of such an agreement within the past twelve month.
- (4) The analysed company holds 5% or more of the share capital of NuWays AG.
- (5) holds (a) a net short position or (b) a net long position of 0.5% of the outstanding share capital of the analysed company.
- (6) or any other person belonging to the same group with it is a market maker or liquidity provider in the financial instruments of the issuer.
- (7) or the analyst has any other significant financial interests relating to the analysed company such as, for example, exercising mandates in the interest of the analysed company.
- (8) The research report has been made available to the analysed company prior to its publication. Thereafter, only factual changes have been made to the report.

Conflicts of interest that existed at the time when this research report was published:

Company	Disclosures
MAX Automation SE	2

Historical target price and	rating changes for MAX Aut	tomation SE			
Company	Date	Analyst	Rating	Target Price	Close
MAX Automation SE	30.11.2023	Wunderlich, Tim	n.a.	EUR 8.20	EUR 5.74
	30.11.2023	Khare, Vaishnavi	n.a.	EUR 8.20	EUR 5.74
	09.11.2023	Wunderlich, Tim	n.a.	EUR 7.30	EUR 5.90
	09.11.2023	Khare, Vaishnavi	n.a.	EUR 7.30	EUR 5.90

Update - 13.03.2024



1. General Information/Liabilities

This research report has been produced for the information purposes of institutional investors only, and is not in any way a personal recommendation, offer or solicitation to buy or sell the financial instruments mentioned herein. The document is confidential and is made available by NuWays AG exclusively to selected recipients in the European Union (EU) or, in individual cases, also in other countries. It is not allowed to pass the research report on to persons other than the intended recipient without the permission of NuWays AG. Reproduction of this document, in whole or in part, is not permitted without prior permission NuWays AG. All rights reserved.

Under no circumstances shall NuWays AG, any of its employees involved in the preparation, have any liability for possible errors or incompleteness of the information included in this research report – neither in relation to indirect or direct nor consequential damages. Liability for damages arising either directly or as a consequence of the use of information, opinions and estimates is also excluded. Past performance of a financial instrument is not necessarily indicative of future performance.

2. Responsibilities

This research report was prepared by the research analyst named on the front page (the "Producer"). The Producer is solely responsible for the views and estimates expressed in this report. The report has been prepared independently. The content of the research report was not influenced by the issuer of the analysed financial instrument at any time. It may be possible that parts of the research report were handed out to the issuer for information purposes prior to the publication without any major amendments being made thereafter.

3. Organisational Requirements

NuWays AG took internal organisational and regulative precautions to avoid or accordingly disclose possible conflicts of interest in connection with the preparation and distribution of the research report. All members of NuWays AG involved in the preparation of the research report are subject to internal compliance regulations. No part of the Producer's compensation is directly or indirectly related to the preparation of this financial analysis. In case a research analyst or a closely related person is confronted with a conflict of interest, the research analyst is restricted from covering this company.

4. Information Concerning the Methods of Valuation/Update

The determination of the fair value per share, i.e. the price target, and the resultant rating is done on the basis of the adjusted free cash flow (adj. FCF) method and on the basis of the discounted cash flow – DCF model. Furthermore, a peer group comparison is made.

The adj. FCF method is based on the assumption that investors purchase assets only at a price (enterprise value) at which the operating cash flow return after taxes on this investment exceeds their opportunity costs in the form of a hurdle rate of 7.5%. The operating cash flow is calculated as EBITDA less maintenance capex and taxes.

Within the framework of the DCF approach, the future free cash flows are calculated initially on the basis of a fictitious capital structure of 100% equity, i.e. interest and repayments on debt capital are not factored in initially. The adjust-

ment towards the actual capital structure is done by discounting the calculated free cash flows with the weighted average cost of capital (WACC), which takes into account both the cost of equity capital and the cost of debt. After discounting, the calculated total enterprise value is reduced by the interest-bearing debt capital in order to arrive at the equity value.

NuWays AG uses the following three-step rating system for the analysed companies:

Buy: Sustainable upside potential of more than 20% within 12 months

Sell: Sustainable downside potential of more than 20% within 12 months.

Hold: Upside/downside potential is limited. No immediate catalyst visible.

The decision on the choice of the financial instruments analysed in this document was solely made by NuWays AG. The opinions and estimates in this research report are subject to change without notice. It is within the discretion of NuWays AG whether and when it publishes an update to this research report, but in general updates are created on a regular basis, after 6 months at the latest. A sensitivity analysis is included and published in company's initial studies.

5. Major Sources of Information

Part of the information required for this research report was made available by the issuer of the financial instrument. Furthermore, this report is based on publicly available sources (such as, for example, Bloomberg, Reuters, VWD-Trader and the relevant daily press) believed to be reliable. NuWays AG has checked the information for plausibility but not for accuracy or completeness.

6. Competent Supervisory Authority

NuWays AG is an affiliated company of Hauck Aufhäuser Lampe Privatbank AG which is under supervision of the BaFin – German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Straße 24 – 28, 60439 Frankfurt a.M.

7. Specific Comments for Recipients Outside of Germany

This research report is subject to the law of the Federal Republic of Germany and the European Union (EU). The distribution of this information to other states in particular to the USA, Canada, Australia and Japan may be restricted or prohibited by the laws applicable within this state. If this communication is distributed in the United Kingdom it is solely directed at (i) investment professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO") or (ii) high net-worth entities as defined in article 49 of the FPO. This document should not be distributed or forwarded, either directly or indirectly, to any other individuals.

8. Miscellaneous

According to Article 4(1) No. i of the delegated regulation 2016/958 supplementing regulation 596/2014 of the European Parliament, further information regarding investment recommendations of the last 12 months are published under: www.nuways-ag.com

Date of publication creation: 13/03/2024 08:00 AM

Date of publication dissemination: 13/03/2024 08:00 AM

Update - 13.03.2024



Contacts

NuWays AG

Mittelweg 16-17 20148 Hamburg Germany +49 170 119 8648 info@nuways-ag.com www.nuways-ag.com



Christian Sandherr Co-CEO/Analyst

christian.sandherr@nuways-ag.com



Frederik Jarchow Co-CEO/Analyst

frederik.jarchow@nuways-ag.com



Philipp Sennewald

Analyst

philipp.sennewald@nuways-ag.com



Henry Wendisch

Analyst

henry.wendisch@nuways-ag.com



Mark Schüssler

Analyst

mark-hendrik.schuessler@nuways-ag.com



Konstantin Völk

Analyst

konstantin.voelk@nuways-ag.com

Find us on Social Media

Instagram



Twitter/X



LinkedIn

